Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 33.27 USD 0.36% Market Closed
Market Cap: 1.9B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SUPN Price Targets Summary
Supernus Pharmaceuticals Inc

Wall Street analysts forecast SUPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUPN is 39.58 USD with a low forecast of 36.36 USD and a high forecast of 46.2 USD.

SUPN Lowest Forecast
Wall Street Target
36.36 USD
9% Upside
SUPN Average Forecast
Wall Street Target
39.58 USD
19% Upside
SUPN Highest Forecast
Wall Street Target
46.2 USD
39% Upside
Lowest
Price Target
36.36 USD
9% Upside
Average
Price Target
39.58 USD
19% Upside
Highest
Price Target
46.2 USD
39% Upside
Supernus Pharmaceuticals Inc Competitors:
Price Targets
ALKEM
Alkem Laboratories Ltd
7% Upside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
31% Upside
NUVB
Nuvation Bio Inc
218% Upside
4506
Sumitomo Pharma Co Ltd
17% Downside
ALKEM
Alkem Laboratories Ltd
7% Upside
B
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
31% Upside
NUVB
Nuvation Bio Inc
218% Upside
4506
Sumitomo Pharma Co Ltd
17% Downside

Revenue
Forecast

Revenue Estimate
Supernus Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Supernus Pharmaceuticals Inc's revenue is 68%. The projected CAGR for the next 3 years is 5%.

68%
Past Growth
5%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Supernus Pharmaceuticals Inc

The compound annual growth rate of Supernus Pharmaceuticals Inc's operating income for the next 3 years is 33%.

N/A
Past Growth
33%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Supernus Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Supernus Pharmaceuticals Inc's net income is 3%. The projected CAGR for the next 3 years is 39%.

3%
Past Growth
39%
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

See Also

Summary
SUPN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUPN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUPN stock valuation using valuation multiples.
Wall Street Estimates
SUPN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUPN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SUPN's stock price target?
Price Target
39.58 USD

According to Wall Street analysts, the average 1-year price target for SUPN is 39.58 USD with a low forecast of 36.36 USD and a high forecast of 46.2 USD.

What is Supernus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
5%

For the last 13 years the compound annual growth rate for Supernus Pharmaceuticals Inc's revenue is 68%. The projected CAGR for the next 3 years is 5%.

What is Supernus Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
33%

The compound annual growth rate of Supernus Pharmaceuticals Inc's operating income for the next 3 years is 33%.

What is Supernus Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
39%

For the last 13 years the compound annual growth rate for Supernus Pharmaceuticals Inc's net income is 3%. The projected CAGR for the next 3 years is 39%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.